491 related articles for article (PubMed ID: 29212525)
21. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
22. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
[TBL] [Abstract][Full Text] [Related]
23. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
[No Abstract] [Full Text] [Related]
24. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with engraftment success of patient-derived xenografts of breast cancer.
Lee J; Lee G; Park HS; Jeong BK; Gong G; Jeong JH; Lee HJ
Breast Cancer Res; 2024 Mar; 26(1):49. PubMed ID: 38515107
[TBL] [Abstract][Full Text] [Related]
26. Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts.
Lefley D; Howard F; Arshad F; Bradbury S; Brown H; Tulotta C; Eyre R; Alférez D; Wilkinson JM; Holen I; Clarke RB; Ottewell P
Breast Cancer Res; 2019 Nov; 21(1):130. PubMed ID: 31783893
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
28. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
29. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
[TBL] [Abstract][Full Text] [Related]
31. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
32. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
[TBL] [Abstract][Full Text] [Related]
33. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
34. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
Gómez-Miragaya J; Morán S; Calleja-Cervantes ME; Collado-Sole A; Paré L; Gómez A; Serra V; Dobrolecki LE; Lewis MT; Diaz-Lagares A; Eroles P; Prat A; Esteller M; González-Suárez E
Mol Cancer Res; 2019 Oct; 17(10):2063-2076. PubMed ID: 31320385
[TBL] [Abstract][Full Text] [Related]
35. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
36. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
[No Abstract] [Full Text] [Related]
37. De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.
Tanaka S; Matsunami N; Morishima H; Oda N; Takashima T; Noda S; Kashiwagi S; Tauchi Y; Asano Y; Kimura K; Fujioka H; Terasawa R; Kawaguchi K; Ikari A; Morimoto T; Michishita S; Kobayashi T; Sakane J; Nitta T; Sato N; Hokimoto N; Nishida Y; Iwamoto M
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1099-1104. PubMed ID: 30963212
[TBL] [Abstract][Full Text] [Related]
38. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
40. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
